Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolent Health, Inc Class A Common Stock (NY:EVH)

8.410 -0.140 (-1.64%)
Streaming Delayed Price Updated: 11:37 AM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Evolent Health, Inc Class A Common Stock

< Previous 1 2 3 4 5 Next >
3 Value Stocks Walking a Fine Line
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
Evolent Health, Amphastar Pharmaceuticals, Iridium, and Magnite Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports,... 
Via StockStory
Topics Artificial Intelligence Government Stocks
Exposures Artificial Intelligence Political Tariff
Reflecting On Healthcare Technology for Providers Stocks’ Q1 Earnings: Evolent Health (NYSE:EVH)
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the healthcare technology for providers industry, including Evolent Health (NYSE:EVH) and its peers. 
Via StockStory
Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the major indices pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that... 
Via StockStory
Topics Bonds Stocks
Exposures Debt Markets US Equities
Earnings Scheduled For May 8, 2025
Via Benzinga
Beyond The Numbers: 18 Analysts Discuss Evolent Health Stock
Via Benzinga
1 Healthcare Stock to Keep an Eye On and 2 to Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Economy Stocks
Exposures COVID-19 Supply Chain US Equities
Expert Outlook: Evolent Health Through The Eyes Of 9 Analysts
Via Benzinga
Evolent Health (NYSE:EVH) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations
Healthcare solutions company Evolent Health (NYSE:EVH) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 24.4% year on year to $483.6 million. Revenue guidance... 
Via StockStory
Evolent Health (EVH) Q1 Earnings Report Preview: What To Look For
Healthcare solutions company Evolent Health (NYSE:EVH) will be announcing earnings results tomorrow after market close. Here’s what investors should know. 
Via StockStory
Earnings Scheduled For February 20, 2025
Via Benzinga
1 Unprofitable Stock Worth Investigating and 2 to Question
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
Winners And Losers Of Q4: Evolent Health (NYSE:EVH) Vs The Rest Of The Healthcare Technology for Providers Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Evolent Health (NYSE:EVH) and... 
Via StockStory
Unpacking Q4 Earnings: Omnicell (NASDAQ:OMCL) In The Context Of Other Healthcare Technology for Providers Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Omnicell (NASDAQ:OMCL) and the best and... 
Via StockStory
Q4 Earnings Highs And Lows: Premier (NASDAQ:PINC) Vs The Rest Of The Healthcare Technology for Providers Stocks
Looking back on healthcare technology for providers stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Premier (NASDAQ:PINC) and its peers. 
Via StockStory
Topics Economy
Exposures Supply Chain
Elevance Health’s (NYSE:ELV) Q1 Sales Top Estimates
Health insurance provider Elevance Health (NYSE:EVH) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 14.5% year on year to $48.77 billion. Its non-GAAP profit of $11.97... 
Via StockStory
Topics Artificial Intelligence Economy Fraud
Exposures Artificial Intelligence Interest Rates Legal
Molina Healthcare, Encompass Health, RadNet, Evolent Health, and Ibotta Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after President Trump criticized the Federal Reserve's approach to interest rate cuts, warning that the pace was slow and could hinder economic growth.... 
Via StockStory
Topics Economy Government World Trade
Exposures Interest Rates Political Tariff
Elevance Health Earnings: What To Look For From ELV
Health insurance provider Elevance Health (NYSE:EVH) will be reporting results tomorrow before market hours. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Healthcare Technology Stocks Q4 In Review: Hims & Hers Health (NYSE:HIMS) Vs Peers
Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. 
Via StockStory
Q4 Rundown: Astrana Health (NASDAQ:ASTH) Vs Other Healthcare Technology for Providers Stocks
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology for providers stocks, including Astrana Health (NASDAQ:ASTH) and its peers. 
Via StockStory
Q4 Earnings Outperformers: Tandem Diabetes (NASDAQ:TNDM) And The Rest Of The Healthcare Technology Stocks
Let’s dig into the relative performance of Tandem Diabetes (NASDAQ:TNDM) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. 
Via StockStory
The Analyst Verdict: Evolent Health In The Eyes Of 16 Experts
Via Benzinga
1 Growth Stock to Stash and 2 to Keep Off Your Radar
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
Exposures COVID-19
Medicare Advantage Rates Expected To Climb Over 5% In 2026, Easing Pressure On Managed Care
CMS raises 2026 Medicare Advantage payments by 5.06%, exceeding projections and benefiting insurers focused on value-based care. 
Via Benzinga
1 Healthcare Stock on Our Watchlist and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Q4 Earnings Review: Healthcare Technology for Providers Stocks Led by Phreesia (NYSE:PHR)
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology for providers stocks, including Phreesia (NYSE:PHR) and its peers. 
Via StockStory
3 Reasons to Sell EVH and 1 Stock to Buy Instead
Evolent Health has gotten torched over the last six months - since September 2024, its stock price has dropped 71.1% to $8.76 per share. This was partly due to its softer quarterly results and may have... 
Via StockStory
Hims & Hers Health (HIMS) To Report Earnings Tomorrow: Here Is What To Expect
Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting earnings tomorrow afternoon. Here’s what investors should know. 
Via StockStory
Evolent Health (EVH) Q4 2024 Earnings Call Transcript
EVH earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Evolent Health (NYSE:EVH) Misses Q4 Sales Targets
Healthcare solutions company Evolent Health (NYSE:EVH) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 16.3% year on year to $646.5 million. Next quarter’s revenue guidance... 
Via StockStory
Topics Economy
Exposures Interest Rates
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.